Testosterone Replacement in Young Male cancer Survivors - TRYMS

Sheffield Teaching Hospitals NHS Foundation Trust0 个研究点目标入组 268 人开始时间: 2011年8月8日最近更新: 2016年12月12日

适应症

试验速览

暂无简介。

•Able and willing to provide written informed consent • Able and willing to comply with all study procedures • Male • Aged between 25 and 50 years • Post-pubertal • Previous testicular cancer, lymphoma or leukaemia • At least 12 months from completion of curative treatment for testicular cancer, lymphoma or leukaemia • A serum testosterone level =7nmol/l and =12nmol/l • If taking any hormone replacement, on stable doses for the last 6 months
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 268
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 0

•Body Mass Index (BMI) of more than 35 kg/m2 • Currently receiving corticosteroid therapy or likely to receive corticosteroids during the trial • Previous testosterone treatment within 12 months of entering the trial • Previous allogeneic bone marrow transplant • A history of hormone-dependent cancer (e.g. prostate or breast cancer) • A history of primary liver tumour • Previous history of hypercalcaemia • Nephrotic syndrome • Diabetes mellitus (type 1 or type 2) • Hypertension • Heart failure • Liver disease • Renal failure • Deep vein thrombosis • Systolic blood pressure > 100 mmHg diastolic or > 160 mmHg systolic after resting and three measurements - Clinically significant abnormal PSA or FBC • Other severe concurrent disease or mental disorder which would affect the collection of study measurements

发起方